Clinical trials: Recurrent Glioma, active
Ependymoma
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells).
- Trial name
- NCT04903080
- Testing
- HER2 Specific CAR T Cell
- Where
- 13 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Children's Oncology Group
BRAF V600 Mutation, Low-grade Glioma
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation.
- Conditions
- BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
- Trial name
- PNOC037 (NCT07110246)
- Testing
- Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI)
- Where
- 12 sites in United States
- Volunteers
- 96 people
- Sponsor
- University of California, San Francisco
Glioblastoma
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in glioblastoma (a malignant tumor, or GBM), when…
- Trial name
- NCT03452579
- Testing
- Nivolumab, Standard Dose Bevacizumab, Low Dose Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- David Peereboom
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of Pembrolizumab and M032 (NSC 733972)
This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma
- Trial name
- NCT05084430
- Testing
- M032, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Glioblastoma
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
This is an open-label, single-arm, dose-escalation and multiple-dose study to evaluate the safety, tolerability, and preliminary efficacy of TX103-CAR-T Cell Injection, a B7-H3-targeting chimeric antigen receptor T-cell (CAR-T)…
- Trial name
- NCT05241392
- Testing
- B7-H3-targeting CAR-T cells/TX103-CAR-T Cell Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment…
- Conditions
- Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma
- Trial name
- NCT01089101
- Testing
- Biospecimen Collection, Selumetinib
- Where
- 17 sites in United States
- Volunteers
- 217 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent…
- Trial name
- NCT07392957
- Testing
- CTX-009, CTX-471
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Washington University School of Medicine
Recurrent Medulloblastoma, Recurrent Ependymoma
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma.
- Trial name
- NCT04743661
- Testing
- Irinotecan, Temozolomide, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pediatric Brain Tumor Consortium
Recurrent High Grade Gliomas, Glioblastoma (GBM)
A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)
ALERT-1 is a Phase 1/2 study evaluating the safety and preliminary anti-tumor activity of SRN-101, an investigational gene therapy, in adults with recurrent high-grade glioma. High-grade glioma is a type of brain cancer.
- Conditions
- Recurrent High Grade Gliomas, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma
- Trial name
- ALERT-1 (NCT07902037)
- Testing
- SRN-101
- Volunteers
- 40 people
- Sponsor
- Siren Biotechnology
Glioblastoma Multiforme
Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
This study will collect blood and urine samples from patients undergoing radiation therapy for glioblastoma multiforme (a type of brain tumor) to investigate the effects of this treatment on blood cells and certain proteins.
- Trial name
- NCT00083512
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with…
- Trial name
- NCT05168423
- Testing
- CART-EGFR-IL13Ra2 Cells
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Pennsylvania
Glioblastoma, Malignant Glioma
CARv3-TEAM-E T Cells in Glioblastoma
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma.
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
- Trial name
- NCT05660369
- Testing
- CARv3-TEAM-E T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Recurrent Malignant Glioma, Glioblastoma
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
GLIOTARG trial is a large single-center observational cohort study designed to investigate chemotherapy and targeted therapy outcomes in recurrent malignant gliomas.
- Conditions
- Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, Pleomorphic Xanthoastrocytoma
- Trial name
- GLIOTARG (NCT07448480)
- Testing
- Bevacizumab-Containing Regimens, Non-Bevacizumab Regimens, BRAF ± MEK Targeted Therapy
- Where
- Russia
- Volunteers
- 1,000 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Astrocytoma, Glioblastoma
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma.
- Conditions
- Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
- Trial name
- NCT05236036
- Testing
- Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 86 people
- Sponsor
- Northwestern University
Glioma, Glioblastoma
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.
- Conditions
- Glioma, Glioblastoma, GBM, Glioma, Malignant
- Trial name
- ENDURANCE (NCT07821112)
- Testing
- GammaTile®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Glioblastoma Multiforme, Relapse
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
The standard of care for glioblastoma (GBM) treatment involves maximal resection followed by concomitant radiotherapy and temozolomide.
- Trial name
- NCT06356883
- Testing
- IA Carboplatin + IA Caelyx, IA Carboplatin + IA Etoposide Phosphate
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Université de Sherbrooke
Brain Tumor, Cancer
000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Protocol # 000860 Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.
- Trial name
- NCT05588141
- Testing
- Zotiraciclib
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM).
- Trial name
- NCT04225039
- Testing
- INCMGA00012, INCAGN01876, SRS
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pennsylvania
Recurrent Glioblastoma
Sacituzumab Govitecan in Recurrent Glioblastoma
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of…
- Trial name
- NCT04559230
- Testing
- Sacituzumab Govitecan
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics